drugset

drugset / Trial / NCT03555955

A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

NCT03555955 ↗

Phase 1 Completed 21 enrolled Jazz Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.

Timeline

Start: 2018-11-20
Primary completion: 2021-05-26
Completion: 2021-05-26

Publications

Solomon SR, Powell BL, Koprivnikar J, Lai C, Male H, Michaelis LC, Newell LF, Sanford D, Jenkins J, Zelaya A, Coppola S, Faderl S, Walter RB. CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial. Cancers (Basel). 2024 Feb 24;16(5):915. doi: 10.3390/cancers16050915.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CPX-351	Other / unclassified	—	Intravenous

Indications